Journal
CANCER LETTERS
Volume 504, Issue -, Pages 91-103Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2021.02.007
Keywords
Osteosarcoma; Drug resistance; MicroRNA; Long noncoding RNA; Circular RNA
Categories
Funding
- National Natural Science Foundation of China [81672176, 81871783, 82072441]
Ask authors/readers for more resources
Osteosarcoma is the most frequent bone malignancy in children and adolescents, with the development of multi-drug resistance posing a major obstacle in improving chemotherapy efficacy. Research has shown that noncoding RNAs play significant roles in osteosarcoma progression and chemosensitivity, highlighting their potential as biomarkers and therapeutic targets for improving patient prognosis.
Osteosarcoma is the most frequent bone malignancy in children and adolescents. Despite advances of surgery and chemotherapy in osteosarcoma over the past decades, overall survival rates of osteosarcoma have reached a plateau. The development of multi-drug resistance (MDR) has become the main obstacle in improving chemotherapeutic effects in osteosarcoma treatment. Therefore, understanding detailed mechanisms of chemoresistance and developing novel therapeutic targets to overcome chemoresistance are crucial to improve the prognosis of osteosarcoma patients. Accumulating evidence has proved that multiple noncoding RNAs (ncRNAs), including microRNAs (miRNAs), long noncoding RNAs (lncRNAs) and circular RNAs (circRNAs) play pivotal roles in osteosarcoma progression. Notably, a great number of ncRNAs are abnormally expressed and can regulate chemosensitivity through various mechanisms in osteosarcoma. In this review, we systematically summarize the roles of ncRNAs as well as the molecular mechanisms in modulating drug resistance of osteosarcoma and discuss the potential roles of ncRNAs as biomarkers and novel therapeutic targets for osteosarcoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available